iShares Biotechnology ETF
431 hedge funds and large institutions have $6B invested in iShares Biotechnology ETF in 2015 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 130 increasing their positions, 152 reducing their positions, and 57 closing their positions.
37% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 57
10% more funds holding in top 10
Funds holding in top 10: 29 → 32 (+3)
4% more funds holding
Funds holding: 414 → 431 (+17)
7% less capital invested
Capital invested by funds: $6.44B → $6B (-$434M)
14% less repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 152
42% less call options, than puts
Call options by funds: $795M | Put options by funds: $1.37B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$383M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$79M |
| 3 |
LPL Financial
San Diego,
California
|
+$63.9M |
| 4 |
D.E. Shaw & Co
New York
|
+$18.6M |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$355M |
| 2 |
Morgan Stanley
New York
|
-$250M |
| 3 |
Citigroup
New York
|
-$223M |
| 4 |
Goldman Sachs
New York
|
-$156M |
| 5 |
JP Morgan Chase
New York
|
-$126M |
IBB Hedge Fund Activity: Q4 2015 in Review
431 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2015, worth a combined $6B — down 6.7% from $6.44B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new IBB positions and 57 closed out — a net gain of 21 holders — while 130 added to existing stakes and 152 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $383M. The largest seller was Credit Suisse, cutting an estimated $355M.
- 431 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2015, up from 414 in Q3 2015.
- Funds reported $6B of iShares Biotechnology ETF stock for Q4 2015, down 6.7% quarter-over-quarter.
- 78 funds opened new iShares Biotechnology ETF positions in Q4 2015 and 57 closed out, a net change of +21 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2015 was BNP Paribas Financial Markets, an estimated $383M added.
- The largest iShares Biotechnology ETF seller in Q4 2015 was Credit Suisse, an estimated $355M sold.
Based on aggregated 13F filings for Q4 2015.